{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:40:39Z","timestamp":1793407239160,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["424778381-TRR 295 A01, A06"],"award-info":[{"award-number":["424778381-TRR 295 A01, A06"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012686","name":"Deutsche Stiftung Neurologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neuroinflammation is deeply intertwined with dopaminergic (DA) neurodegeneration in Parkinson\u2019s disease (PD). We tested whether delphinidin, an anthocyanidin with reported inflammasome\/NF-\u03baB modulatory activity, alters neuroinflammation and nigrostriatal integrity in a progressive AAV1\/2-A53T \u03b1-synuclein (h\u03b1SYN) mouse model. Once-daily intraperitoneal delphinidin for nine weeks modestly ameliorated asymmetric forepaw use, attenuated the h\u03b1SYN-induced loss of striatal TH\u207a terminal density, and was associated with modest alterations in dopamine turnover, yet did not prevent the loss of DA neurons in the substantia nigra (SN). On the immunological level, delphinidin attenuated the innate immune response by reducing the number and activity of CD11b\n                    <jats:sup>+<\/jats:sup>\n                    microglia in both the SN and striatum. In contrast, CD4\n                    <jats:sup>+<\/jats:sup>\n                    -mediated adaptive inflammation remained unchanged, while the number of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells increased in the SN. Notably, approximately 48% of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in the SN of these mice were identified as CD8\n                    <jats:sup>+<\/jats:sup>\n                    CD122\n                    <jats:sup>+<\/jats:sup>\n                    regulatory T cells, known for their anti-inflammatory properties. In conclusion, delphinidin was associated with a partial attenuation of neuroinflammatory changes and a context-dependent shift towards a more anti-inflammatory CD8\u207aCD122\n                    <jats:sup>+<\/jats:sup>\n                    T cell phenotype in the SN. However, these changes did not translate into protection of SN DA somata, revealing a dissociation between striatal terminal preservation and nigral cell body survival, and underscoring the limitations of targeting innate immunity alone under the current dosing paradigm.\n                  <\/jats:p>","DOI":"10.1038\/s41531-025-01244-0","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T06:55:33Z","timestamp":1768200933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Delphinidin modulates neuroinflammation and behavioral deficits in a Parkinson\u2019s disease mouse model"],"prefix":"10.1038","volume":"12","author":[{"given":"A.","family":"Grotemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Frie\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Roewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. E.","family":"Bankoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Badr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Stopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Roewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. W.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"1244_CR1","doi-asserted-by":"publisher","first-page":"878771","DOI":"10.3389\/fimmu.2022.878771","volume":"13","author":"A Grotemeyer","year":"2022","unstructured":"Grotemeyer, A., McFleder, R. L., Wu, J., Wischhusen, J. & Ip, C. W. Neuroinflammation in Parkinson\u2019s disease\u2014putative pathomechanisms and targets for disease-modification. Front. Immunol. 13, 878771 (2022).","journal-title":"Front. Immunol."},{"key":"1244_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"1244_CR3","doi-asserted-by":"crossref","unstructured":"Karikari, A. A. et al. Neurodegeneration by \u03b1-synuclein-specific T cells in AAV-A53T-\u03b1-synuclein Parkinson\u2019s disease mice. Brain Behav. Immun. 101, 194\u2013210 (2022).","DOI":"10.1016\/j.bbi.2022.01.007"},{"key":"1244_CR4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology 38, 1285\u20131285 (1988).","journal-title":"Neurology"},{"key":"1244_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?. Lancet Neurol. 8, 382\u2013397 (2009).","journal-title":"Lancet Neurol."},{"key":"1244_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P.-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1244_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98437-3","volume":"11","author":"W Zeng","year":"2021","unstructured":"Zeng, W. et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages. Sci. Rep. 11, 19305 (2021).","journal-title":"Sci. Rep."},{"key":"1244_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fmolb.2020.00037","volume":"7","author":"J Jiao","year":"2020","unstructured":"Jiao, J., Zhao, G., Wang, Y., Ren, P. & Wu, M. MCC950, a selective inhibitor of nlrp3 inflammasome, reduces the inflammatory response and improves neurological outcomes in mice model of spinal cord injury. Front. Mol. Biosci. 7, 37 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"1244_CR9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","volume":"73","author":"SE Corcoran","year":"2021","unstructured":"Corcoran, S. E., Halai, R. & Cooper, M. A. Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950. Pharm. Rev. 73, 968\u20131000 (2021).","journal-title":"Pharm. Rev."},{"key":"1244_CR10","first-page":"828","volume":"38","author":"GPJ Hout","year":"2017","unstructured":"Hout, G. P. J. et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur. Hear. J. 38, 828\u2013836 (2017).","journal-title":"Eur. Hear. J."},{"key":"1244_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02419-9","volume":"19","author":"K-P Chen","year":"2022","unstructured":"Chen, K.-P. et al. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington\u2019s disease. J. Neuroinflammation 19, 56 (2022).","journal-title":"J. Neuroinflammation"},{"key":"1244_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12974-023-02759-0","volume":"20","author":"A Grotemeyer","year":"2023","unstructured":"Grotemeyer, A. et al. Inflammasome inhibition protects dopaminergic neurons from \u03b1-synuclein pathology in a model of progressive Parkinson\u2019s disease. J. Neuroinflamm 20, 79 (2023).","journal-title":"J. Neuroinflamm"},{"key":"1244_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248\u2013255 (2015).","journal-title":"Nat. Med."},{"key":"1244_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah4066","volume":"10","author":"R Gordon","year":"2018","unstructured":"Gordon, R. et al. Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 10, eaah4066 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1244_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","volume":"17","author":"MSJ Mangan","year":"2018","unstructured":"Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov. 17, 588\u2013606 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1244_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/metabo14040203","volume":"14","author":"I Behrendt","year":"2024","unstructured":"Behrendt, I. et al. Grape\/blueberry anthocyanins and their gut-derived metabolites attenuate LPS\/nigericin-induced inflammasome activation by inhibiting ASC speck formation in THP-1 monocytes. Metabolites 14, 203 (2024).","journal-title":"Metabolites"},{"key":"1244_CR17","doi-asserted-by":"publisher","first-page":"9534","DOI":"10.1039\/D3FO03015F","volume":"14","author":"M Villalva","year":"2023","unstructured":"Villalva, M. et al. Polyphenols as NLRP3 inflammasome modulators in cardiometabolic diseases: a review of in vivo studies. Food Funct. 14, 9534\u20139553 (2023).","journal-title":"Food Funct."},{"key":"1244_CR18","doi-asserted-by":"publisher","first-page":"746881","DOI":"10.3389\/fnut.2022.746881","volume":"9","author":"A Husain","year":"2022","unstructured":"Husain, A. et al. Chemistry and pharmacological actions of delphinidin, a dietary purple pigment in anthocyanidin and anthocyanin forms. Front. Nutr. 9, 746881 (2022).","journal-title":"Front. Nutr."},{"key":"1244_CR19","doi-asserted-by":"crossref","unstructured":"Mattioli, R., Francioso, A., Mosca, L. & Silva, P. Anthocyanins: a comprehensive review of their chemical properties and health effects on cardiovascular and neurodegenerative diseases. Molecules 25, 3809 (2020).","DOI":"10.3390\/molecules25173809"},{"key":"1244_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/rheumatology\/kes363","volume":"52","author":"A Haseeb","year":"2013","unstructured":"Haseeb, A., Chen, D. & Haqqi, T. M. Delphinidin inhibits IL-1\u03b2-induced activation of NF-\u03baB by modulating the phosphorylation of IRAK-1(Ser376) in human articular chondrocytes. Rheumatol. Oxf. Engl. 52, 998\u20131008 (2013).","journal-title":"Rheumatol. Oxf. Engl."},{"key":"1244_CR21","first-page":"5583","volume":"14","author":"C-H Wang","year":"2017","unstructured":"Wang, C.-H., Zhu, L.-L., Ju, K.-F., Liu, J.-L. & Li, K.-P. Anti-inflammatory effect of delphinidin on intramedullary spinal pressure in a spinal cord injury rat model. Exp. Ther. Med. 14, 5583\u20135588 (2017).","journal-title":"Exp. Ther. Med."},{"key":"1244_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nri2423","volume":"8","author":"S Ghosh","year":"2008","unstructured":"Ghosh, S. & Hayden, M. S. New regulators of NF-\u03baB in inflammation. Nat. Rev. Immunol. 8, 837\u2013848 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1244_CR23","doi-asserted-by":"publisher","first-page":"18754","DOI":"10.1073\/pnas.0704908104","volume":"104","author":"A Ghosh","year":"2007","unstructured":"Ghosh, A. et al. Selective inhibition of NF-\u03baB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson\u2019s disease. Proc. Natl. Acad. Sci. USA 104, 18754\u201318759 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1244_CR24","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3390\/molecules25194382","volume":"25","author":"S Aryal","year":"2020","unstructured":"Aryal, S., Skinner, T., Bridges, B. & Weber, J. T. The pathology of Parkinson\u2019s disease and potential benefit of dietary polyphenols. Molecules 25, 4382 (2020).","journal-title":"Molecules"},{"key":"1244_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-017-0416-x","volume":"5","author":"CW Ip","year":"2017","unstructured":"Ip, C. W. et al. AAV1\/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson\u2019s disease. Acta Neuropathol. Commun. 5, 11 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"1244_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41531-024-00767-2","volume":"10","author":"A Grotemeyer","year":"2024","unstructured":"Grotemeyer, A. et al. Standardized wireless deep brain stimulation system for mice. npj Park. \u2019s. Dis. 10, 153 (2024).","journal-title":"npj Park. \u2019s. Dis."},{"key":"1244_CR27","doi-asserted-by":"crossref","unstructured":"Galiano-Landeira, J., Torra, A., Vila, M. & Bov\u00e9, J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain 143, 3717\u20133733 (2020).","DOI":"10.1093\/brain\/awaa269"},{"key":"1244_CR28","first-page":"182","volume":"119","author":"V Brochard","year":"2009","unstructured":"Brochard, V. et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Investig. 119, 182\u2013192 (2009).","journal-title":"J. Clin. Investig."},{"key":"1244_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.stem.2018.06.015","volume":"23","author":"A Sommer","year":"2018","unstructured":"Sommer, A. et al. Th17 Lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson\u2019s disease. Cell Stem Cell 23, 123\u2013131.e6 (2018).","journal-title":"Cell Stem Cell"},{"key":"1244_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/mds.27690","volume":"34","author":"CW Olanow","year":"2019","unstructured":"Olanow, C. W. Levodopa is the best symptomatic therapy for PD: nothing more, nothing less. Mov. Disord. 34, 812\u2013815 (2019).","journal-title":"Mov. Disord."},{"key":"1244_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577543","volume":"354","author":"S Huang","year":"2021","unstructured":"Huang, S. et al. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson\u2019s disease. J. Neuroimmunol. 354, 577543 (2021).","journal-title":"J. Neuroimmunol."},{"key":"1244_CR32","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S.-C. NF-\u03baB signaling in inflammation. Signal Transduct. Target. Ther. 2, 17023 (2017).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1244_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s11658-023-00462-9","volume":"28","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell. Mol. Biol. Lett. 28, 51 (2023).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"1244_CR34","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41593-025-01955-w","volume":"28","author":"J Groh","year":"2025","unstructured":"Groh, J. et al. Microglia activation orchestrates CXCL10-mediated CD8+ T cell recruitment to promote aging-related white matter degeneration. Nat. Neurosci. 28, 1160\u20131173 (2025).","journal-title":"Nat. Neurosci."},{"key":"1244_CR35","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neuron.2022.12.009","volume":"111","author":"Z Shi","year":"2023","unstructured":"Shi, Z. et al. Microglia drive transient insult-induced brain injury by chemotactic recruitment of CD8+ T lymphocytes. Neuron 111, 696\u2013710.e9 (2023).","journal-title":"Neuron"},{"key":"1244_CR36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fncel.2019.00514","volume":"13","author":"C-Y Liu","year":"2019","unstructured":"Liu, C.-Y., Wang, X., Liu, C. & Zhang, H.-L. Pharmacological targeting of microglial activation: new therapeutic approach. Front. Cell. Neurosci. 13, 514 (2019).","journal-title":"Front. Cell. Neurosci."},{"key":"1244_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fimmu.2015.00494","volume":"6","author":"J Liu","year":"2015","unstructured":"Liu, J., Chen, D., Nie, G. D. & Dai, Z. CD8+CD122+ T-cells: a newly emerging regulator with central memory cell phenotypes. Front. Immunol. 6, 494 (2015).","journal-title":"Front. Immunol."},{"key":"1244_CR38","doi-asserted-by":"publisher","first-page":"708874","DOI":"10.3389\/fimmu.2021.708874","volume":"12","author":"S Mishra","year":"2021","unstructured":"Mishra, S., Srinivasan, S., Ma, C. & Zhang, N. CD8+ regulatory T cell \u2013 a mystery to be revealed. Front. Immunol. 12, 708874 (2021).","journal-title":"Front. Immunol."},{"key":"1244_CR39","doi-asserted-by":"publisher","first-page":"111853","DOI":"10.1016\/j.nut.2022.111853","volume":"105","author":"BRO Neves","year":"2023","unstructured":"Neves, B. R. O., de Freitas, S., Borelli, P., Rogero, M. M. & Fock, R. A. Delphinidin-3-O-glucoside in vitro suppresses NF-\u03baB and changes the secretome of mesenchymal stem cells affecting macrophage activation. Nutrition 105, 111853 (2023).","journal-title":"Nutrition"},{"key":"1244_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11481-019-09888-5","volume":"15","author":"Y Huang","year":"2020","unstructured":"Huang, Y., Liu, Z., Cao, B.-B., Qiu, Y.-H. & Peng, Y.-P. Treg cells attenuate neuroinflammation and protect neurons in a mouse model of Parkinson\u2019s disease. J. Neuroimmune Pharmacol. 15, 224\u2013237 (2020).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"1244_CR41","doi-asserted-by":"publisher","first-page":"iv91","DOI":"10.1136\/ard.2005.042564","volume":"64","author":"N Beyersdorf","year":"2005","unstructured":"Beyersdorf, N., Hanke, T., Kerkau, T. & H\u00fcnig, T. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann. Rheum. Dis. 64, iv91 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"1244_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02685-7","volume":"19","author":"M Badr","year":"2022","unstructured":"Badr, M. et al. Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-\u03b1-synuclein Parkinson\u2019s disease mice. J. Neuroinflammation 19, 319 (2022).","journal-title":"J. Neuroinflammation"},{"key":"1244_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1515\/nipt-2022-0001","volume":"1","author":"M Markovic","year":"2022","unstructured":"Markovic, M. et al. Interleukin-2 expands neuroprotective regulatory T cells in Parkinson\u2019s disease. Neuroimmune Pharmacol. Ther. 1, 43\u201350 (2022).","journal-title":"Neuroimmune Pharmacol. Ther."},{"key":"1244_CR44","doi-asserted-by":"publisher","first-page":"1281763","DOI":"10.3389\/fncel.2023.1281763","volume":"17","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z., Duan, Z. & Cui, Y. CD8+ T cells in brain injury and neurodegeneration. Front. Cell. Neurosci. 17, 1281763 (2023).","journal-title":"Front. Cell. Neurosci."},{"key":"1244_CR45","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1084\/jem.20040395","volume":"200","author":"M Rifa\u2019i","year":"2004","unstructured":"Rifa\u2019i, M., Kawamoto, Y., Nakashima, I. & Suzuki, H. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J. Exp. Med. 200, 1123\u20131134 (2004).","journal-title":"J. Exp. Med."},{"key":"1244_CR46","unstructured":"Paxinos, G. & Franklin, K. B. J. The Mouse Brain in Stereotaxic Coordinates (Academic Press, 2013)."},{"key":"1244_CR47","doi-asserted-by":"crossref","unstructured":"Rauschenberger, L. et al. Striatal dopaminergic dysregulation and dystonia-like movements induced by sensorimotor stress in a pharmacological mouse model of rapid-onset dystonia-parkinsonism. Exp. Neurol. 323, 113109 (2019).","DOI":"10.1016\/j.expneurol.2019.113109"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01244-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01244-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01244-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:04:19Z","timestamp":1769695459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01244-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01244-0","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}